

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

DC 02/20

Licensee

31/7/2

In accordance with letter dated,

December 14, 2007

3. License number 13-00418-02 is amended in its entirety to read as follows:

4. Expiration date **May 31, 2011**5. Docket No. 030-01581
Reference No.

1. St. Joseph Health System LLC
d/b/a St. Joseph Medical Center
2. 700 Broadway
Fort Wayne, IN 46802

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

- A. Any byproduct material permitted by 10 CFR 35.100
- B. Any byproduct material permitted by 10 CFR 35.200
- C. Any byproduct material permitted by 10 CFR 35.300
- D. Any byproduct material permitted by 10 CFR 35.500

- A. Any
- B. Any
- C. Any
- D. Sealed source (Gammatron, Inc, Model OS-213A)

- A. As needed
- B. As needed
- C. As needed
- D. One source not to exceed 300 millicuries

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. For storage only incident to disposal.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-00418-02Docket or Reference Number
030-01581

Amendment No. 61

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 700 Broadway, Fort Wayne, Indiana.
11. The Radiation Safety Officer for this license is Dakshesh Patel, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Brett Hagedorn M.D.

10 CFR 35.100, 35.200.

John Pasalich, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Stephen R. Phillip, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Marc Thomas, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

David Sorg, M.D.

Oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries.

Diane D. Daly, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Frederick N. Vandeman, M.D.

10 CFR 35.100, 35.200, 35.300 (Oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.

Christopher Kowalski, M.D.

10 CFR 35.100, 35.200.

Joseph R. Decamp, M.D.

10 CFR 35.100, 35.200, 35.500 and oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries.

John L. Bormann, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Michael E. Parker, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Michael W. Tanksley, M.D.

10 CFR 35.100, 35.200 and 35.300 (oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-00418-02Docket or Reference Number
030-01581

Amendment No. 61

Authorized UsersMaterial and Use

Andre B. Stovall, M.D.	10 CFR 35.100, 35.200.
Pamela Lee Strange, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
John Rock, M.D.	10 CFR 35.100 and 35.200.
Richard P. Stephens, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
James C. Wehrenberg, M.D.	10 CFR 35.100 and 35.200.
James A. Arata, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
David B. Janizek, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Christine Anne Tremper, M.D.	10 CFR 35.100 and 35.200.
Randall J. Phillips, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
John R. Kim, M.D.	10 CFR 35.100, 35.200, 35.300 (oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.
Gina Hook, M.D.	10 CFR 35.100 and 35.200.
Richard Sibley, M.D.	10 CFR 35.100 and 35.200.
Dakshesh Patel, M.D.	10 CFR 35.100 and 35.200.
Shilpa Kashyap, M.D.	10 CFR 35.100 and 35.200.
H. Steven Beyer, M.D.	10 CFR 35.300 ().
Eric V. Heatwole, M.D.	10 CFR 35.100 and 35.200.
Shawn Johnson, M.D.	10 CFR 35.100, 35.200, 35.300.
Brian Kim, M.D.	10 CFR 35.100 and 35.200
Sandeep S. Ahluwalia, M.D.	10 CFR 35.100 and 35.200
John C. Lacunza, M.D.	10 CFR 35.100 and 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-00418-02Docket or Reference Number
030-01581


Amendment No. 61

13. For iodine-131 therapeutic procedures that do not meet the criteria of 10 CFR 35.75, the licensee shall implement the procedures in Appendix P, "Model Procedure for Radiation Safety During Iodine Therapy", found in Regulatory Guide 10.8, Revision 2, dated August 1987.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated December 26, 2000.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAR 13 2008

By

Toye L. Simmons
Materials Licensing Branch
Region III